ClinicalTrials.gg
Active, not recruitingNCT04546009Updated Nov 12, 2026

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

A Phase 3 interventional study of Giredestrant and Giredestrant-matched Placebo in Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, sponsored by Hoffmann-La Roche. Active, not recruiting at 256 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Study completion moved2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
992
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing giredestrant in Breast Neoplasms — 4 open to participants now, 12 under way, 7 of them phase 3. giredestrant · Breast Neoplasms.

Enrollment
4th of 16
992 · median 302
Started
2020
with 2 others
Phase 3
7 of 16
2 open now
Primary completion
2026-01
later than 3 of 11 live
Registered
4th of 16
by date
Lead sponsor
8 of 16
Hoffmann-La Roche

Among the 16 studies testing giredestrant in Breast Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2020, is one of 7 in phase 3, reaches primary completion later than 3 of the 11 other live ones, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 16 studies testing giredestrant in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About giredestrant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing giredestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.

03

Conditions studied

  • Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For women who are premenopausal or perimenopausal and for men: treatment with approved LHRH agonist therapy for the duration of study treatment
  • Locally advanced (recurrent or progressed) or adenocarcinoma of the breast, not amenable to treatment with curative intent
  • Documented ER-positive tumor and -negative tumor, assessed locally
  • Patients who have bilateral breast cancers which are both ER-positive and HER2-negative can be included in the study because the metastases are suitably targeted by the study treatments. If patients have bilateral tumors which are of different biomarker status, then proof of the ER and HER2 status of the metastases is required for study entry
  • No history of systemic anti-cancer therapy for locally advanced (recurrent or progressed) or metastatic disease
  • Disease recurrence from early-stage breast cancer after standard endocrine therapy meeting the protocol-defined criteria of having received at least 24 months of treatment without disease progression during treatment and a disease-free interval since the completion of treatment that was greater than 12 months
  • as defined per v.1.1 or bone only disease which must have at least one predominantly lytic bone lesion confirmed by CT or MRI which can be followed
  • Performance Status 0-1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Disease recurrence during or within 12 months of completing prior or adjuvant treatment with any CDK4/6 inhibitor
  • Prior treatment with a selective estrogen receptor degrader (SERD)
  • Treatment with any therapy within 28 days prior to study treatment
  • Treatment with strong inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization
  • Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
  • Known active uncontrolled or symptomatic , carcinomatous meningitis, or
  • Active cardiac disease or history of cardiac dysfunction, as defined in the protocol
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
992 participants (actual)

Study arms

  • Experimental
    Giredestrant + Letrozole-matched Placebo + Palbociclib

    Drug: Giredestrant · Drug: Letrozole-matched Placebo · Drug: Palbociclib · Drug: LHRH Agonist

  • Active comparator
    Letrozole + Giredestrant-matched Placebo + Palbociclib

    Drug: Giredestrant-matched Placebo · Drug: Letrozole · Drug: Palbociclib · Drug: LHRH Agonist

Interventions

  • Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

    Also known as: GDC-9545, RO7197597, RG6171

  • DrugGiredestrant-matched Placebo

    Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

  • Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

  • DrugLetrozole-matched Placebo

    Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

  • Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.

  • Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1

    Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)

Secondary outcomes

  1. Overall Survival

    Time frame: From randomization to death from any cause (up to 78 months)

  2. Objective Response Rate, as Determined by the Investigator According to RECIST v1.1

    The objective response rate is defined as the percentage of participants with a complete response or partial response on two consecutive occasions at least (≥)4 weeks apart.

    Time frame: From randomization until disease progression or death (up to 78 months)

  3. Duration of Response, as Determined by the Investigator According to RECIST v1.1

    Time frame: From first occurrence of documented objective response to disease progression or death from any cause, whichever occurs first (up to 78 months)

  4. Clinical Benefit Rate, as Determined by the Investigator According to RECIST v1.1

    The clinical benefit rate is defined as the percentage of participants with stable disease for ≥24 weeks or a complete response or partial response.

    Time frame: From randomization until disease progression or death (up to 78 months)

  5. Time to Confirmed Deterioration in Pain Level, Defined as the Time to First Documented ≥2-Point Increase from Baseline in the 'Worst Pain' Item from the Brief Pain Inventory-Short Form (BPI-SF) Questionnaire

    Time frame: From Baseline until treatment discontinuation (up to 78 months)

  6. Time to Confirmed Deterioration in Pain Presence and Interference, Defined as the Time to First Documented ≥10-Point Increase from Baseline in the EORTC QLQ-C30 Linearly Transformed Pain Scale Score

    EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire

    Time frame: From Baseline until treatment discontinuation (up to 78 months)

  7. Time to Confirmed Deterioration in Physical Functioning, Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed Physical Functioning Scale Score

    Time frame: From Baseline until treatment discontinuation (up to 78 months)

  8. Time to Confirmed Deterioration in Role Functioning, Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed Role Functioning Scale Score

    Time frame: From Baseline until treatment discontinuation (up to 78 months)

  9. Time to Confirmed Deterioration in Global Health Status and Quality of Life (GHS/QoL), Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed GHS/QoL Scale Score

    Time frame: From Baseline until treatment discontinuation (up to 78 months)

  10. Number of Participants with Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)

    Time frame: From treatment initiation until 30 days after the final dose of study treatment (up to 78 months)

  11. Number of Participants with Vital Sign Abnormalities Over the Course of the Study

    Vital signs include respiratory rate, pulse rate, and systolic and diastolic blood pressure while the participant is in a seated position, and temperature.

    Time frame: Baseline, Days 1 and 15 of Cycles 1 and 2, and Day 1 of each cycle thereafter until treatment discontinuation (1 cycle is 28 days)

  12. Plasma Concentration of Giredestrant at Specified Timepoints

    Time frame: Days 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 8, and 16 (1 cycle is 28 days)

  13. Plasma Concentration of Palbociclib at Specified Timepoints

    Time frame: Days 1 and 15 of Cycle 1 (1 cycle is 28 days)

07

Study locations

256 sites

Showing the first 100 of 256 sites across 30 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jan 2026, 63 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 63 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2027 → Jul 2028, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2020
First posted
Sep 11, 2020
StartActual
Oct 9, 2020
Primary completionActual
Jan 30, 2026
CompletionEst.
Jul 28, 2028was Jul 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 United States, 1 Denmark)
  • Dana Farber Cancer Institute · Boston, United States
  • Sjællands Universitetshospital, Køge;Onkologisk Afdeling · Køge, Denmark
Show 1 removed
  • Sjællands Universitetshospital, Næstved · Næstved, Denmark
Nov 12, 2026
Study completion
Jul 31, 2027→Jul 28, 2028
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    2 sites added, 1 site removed
    Show 2 added (1 United States, 1 Denmark)
    • Dana Farber Cancer Institute · Boston, United States
    • Sjællands Universitetshospital, Køge;Onkologisk Afdeling · Køge, Denmark
    Show 1 removed
    • Sjællands Universitetshospital, Næstved · Næstved, Denmark
    Study completion Jul 31, 2027→Jul 28, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04546009
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 11, 2020
Start date
Oct 9, 2020
Primary completion
Jan 30, 2026
Completion
Jul 28, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Giredestrant

Start the discussion